If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

Share Price is delayed by 15 minutes
Get Live Data
400.00    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 10.00 (2.532%)
Market Cap: £191.99m
TSTL Live PriceLast checked at - London Stock Exchange

Intraday Tristel Share Chart

Director/PDMR Shareholding

26 Mar 2025 10:30

RNS Number : 3167C
Tristel PLC
26 March 2025
 

Tristel plc

("Tristel" or the "Company")

 

Director/PDMR Shareholding

CEO buys shares

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces that Matthew Sassone, Chief Executive Officer of the Company, has purchased 3,500 ordinary shares of 1 penny each in the Company ("Ordinary Shares") at a price of 310 pence per Ordinary Share.

 

As a result, Matthew Sassone's beneficial interest in the Company is 3,500 Ordinary Shares, representing 0.007 per cent. of the total issued share capital.

 

 

 

For further information please contact:

 

Tristel plc

Via Walbrook PR

Matt Sassone, Chief Executive Officer

www.investors.tristel.com

Liz Dixon, Chief Financial Officer

Walbrook PR Ltd

Tel: 020 7933 8780 or tristel@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Applegarth

Mob: 07584 391303

Cavendish Capital Markets Limited

Tel: 020 7220 0500

Geoff Nash / Camilla Hume / Trisyia Jamaludin (Corporate Finance)

Sunila de Silva (ECM)

Louise Talbot (Sales)

 

About Tristel plc

Tristel plc is a global infection prevention company focussed on the manufacture and supply of products using its unique proprietary chlorine dioxide (ClO2) chemistry. The Company is a market leader in manual decontamination of medical devices, supplying hospitals under the Tristel brand, and under the Cache brand provides products for sporicidal surface disinfection, in a format which is a sustainable alternative to commonly used pre-wetted plastic wipes.

 

Tristel's head office and manufacturing facility is located in Snailwell, near Cambridge, and operates globally employing approximately 250 people across 14 subsidiaries selling into 40 countries.

 

The Company has been listed on the London Stock Exchange's AIM market since 2005 (AIM: TSTL).

 

For more information about Tristel's product range please visit: https://tristel.com

  

 

 

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014 which forms part of UK Law by virtue of the European Union (Withdrawal) Act 2018.

 

 

1. 

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Matthew Sassone

2. 

Reason for the Notification

a)

Position/status

CEO

b)

Initial notification/Amendment

Initial notification

3. 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Tristel plc

b)

LEI

2138009DZ4LH9CZGF662

4. 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary shares of 1p each

Identification code

GB00B07RVT99 

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

310 pence, 3,500 shares

 

 

d)

Aggregated information:

· Aggregated volume

· Price

See above

 

e)

Date of the transaction

26 March 2025

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHZZGZFGVFGKZM
Date   Source Headline
9th Jun 20151:44 pmRNSTristel welcomes Cardiff University wipes study
3rd Jun 201512:20 pmRNSIssue of Equity
22nd May 201511:19 amRNSIssue of Equity
21st May 20157:00 amRNSTrading update
8th May 20157:00 amRNSIssue of Equity
4th Mar 20157:00 amRNSIssue of Equity/Director dealing
26th Feb 20157:01 amRNSInvestor Presentation
25th Feb 20157:00 amRNSHalf Yearly Report
6th Feb 20157:00 amRNSInvestor Results Presentation
28th Jan 20157:00 amRNSIssue of Equity
24th Dec 201411:27 amRNSGrant of Share Options
23rd Dec 20142:38 pmRNSDirector/PDMR Shareholding
16th Dec 201411:53 amRNSResult of AGM
16th Dec 20147:00 amRNSAGM Statement
21st Nov 20147:00 amRNSPosting of Annual Report & Notice of AGM
17th Nov 20143:27 pmRNSIssue of Equity
11th Nov 20147:00 amRNSNZ ENT study shows Tristel Wipes System benefits
3rd Nov 20146:02 pmRNSDirector's Shareholding
20th Oct 201411:56 amRNSIssue of Equity
13th Oct 20147:00 amRNSFinal Results
29th Sep 20147:00 amRNSInvestor Results Presentation
19th Aug 20147:00 amRNSMarket leadership in UK ENT market
28th Jul 20147:00 amRNSPre-close trading update
7th Jul 201410:03 amRNSIssue of Equity
23rd Jun 20148:30 amRNSIssue of Equity
18th Jun 201411:16 amRNSHolding(s) in Company
10th Jun 20147:00 amRNSTrading Update
22nd May 201412:37 pmRNSIssue of Equity
28th Apr 20147:00 amRNSTrading update
24th Apr 20147:00 amRNSSuccess in controlling Clostridium difficile rates
13th Mar 20147:00 amRNSPublic Health England tackle disease threats
3rd Mar 20147:01 amRNSGrant of Share Options
3rd Mar 20147:00 amRNSHalf Yearly Report
13th Feb 20147:00 amRNSInvestor Results Presentation
22nd Jan 20147:00 amRNSTrading Update and notice of results
10th Dec 20132:14 pmRNSResult of AGM
10th Dec 20137:00 amRNSAGM Statement
15th Nov 20137:00 amRNSPosting of Annual Report & Notice of AGM
18th Oct 20137:00 amRNSPeer-reviewed published article
14th Oct 20137:00 amRNSFinal Results
22nd Jul 20137:00 amRNSTrading Update & Notice of Results
28th May 20132:19 pmRNSDirector/PDMR Shareholding
29th Apr 20132:53 pmRNSHolding(s) in Company
15th Apr 20131:47 pmRNSHolding(s) in Company
10th Apr 201311:45 amRNSHolding(s) in Company
9th Apr 201311:18 amRNSDirectors' Shareholdings
21st Mar 20132:44 pmRNSHolding(s) in Company
4th Mar 20139:28 amRNSDirector Shareholding
4th Mar 20137:00 amRNSHalf Yearly Report
14th Feb 20137:00 amRNSTrading update and notice of results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.